Ubs Asset Management Americas Inc Madrigal Pharmaceuticals, Inc. Transaction History
Ubs Asset Management Americas Inc
- $477 Billion
- Q2 2025
A detailed history of Ubs Asset Management Americas Inc transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 39,809 shares of MDGL stock, worth $17.9 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
39,809
Previous 26,363
51.0%
Holding current value
$17.9 Million
Previous $8.73 Million
37.96%
% of portfolio
0.0%
Previous 0.0%
Shares
21 transactions
Others Institutions Holding MDGL
# of Institutions
356Shares Held
23.2MCall Options Held
738KPut Options Held
473K-
Janus Henderson Group PLC London, X02.19MShares$985 Million0.34% of portfolio
-
John Paulson Paulson & Co. Inc. | New York, Ny2.09MShares$940 Million32.86% of portfolio
-
Rtw Investments, LP New York, NY1.99MShares$896 Million9.27% of portfolio
-
Baker Bros. Advisors LP New York, NY1.98MShares$888 Million6.06% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.88MShares$844 Million0.01% of portfolio
About MADRIGAL PHARMACEUTICALS, INC.
- Ticker MDGL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 17,103,400
- Market Cap $7.69B
- Description
- Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...